KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Operating Expenses (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Operating Expenses data on record, last reported at $57.8 million in Q4 2025.

  • For Q4 2025, Operating Expenses fell 64.58% year-over-year to $57.8 million; the TTM value through Dec 2025 reached $599.6 million, up 17.21%, while the annual FY2025 figure was $599.6 million, 17.21% up from the prior year.
  • Operating Expenses reached $57.8 million in Q4 2025 per PACB's latest filing, up from $54.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $427.6 million in Q1 2025 and bottomed at $46.7 million in Q1 2021.
  • Average Operating Expenses over 5 years is $106.2 million, with a median of $89.3 million recorded in 2021.
  • The widest YoY moves for Operating Expenses: up 361.51% in 2025, down 67.25% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $81.4 million in 2021, then increased by 13.24% to $92.2 million in 2022, then increased by 5.31% to $97.1 million in 2023, then skyrocketed by 67.92% to $163.1 million in 2024, then plummeted by 64.58% to $57.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $57.8 million in Q4 2025, $54.8 million in Q3 2025, and $59.5 million in Q2 2025.